Neuronal acetylcholine receptor subunit beta-2


  • Accession: P17787
  • Swissprot: ACHB2_HUMAN
  • Organism: Homo sapiens
  • Gene: CHRNB2
  • Target class: Ion channel

Drug Relations:

Devices or delivery systems used to aid in ending a TOBACCO habit. Bioactivity details MOA
A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION. Bioactivity details MOA
A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. Bioactivity details MOA
A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE. Bioactivity details MOA
A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS. Bioactivity details MOA
from Chinese herb Cyclea hainanensis Mrr Bioactivity details MOA
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients. Bioactivity details MOA
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool. Bioactivity details MOA
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. Bioactivity details MOA
An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. Bioactivity details MOA
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. Bioactivity details MOA
A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release. Bioactivity details MOA
A piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent (NEUROMUSCULAR NONDEPOLARIZING AGENTS). It is used as a muscle relaxant during ANESTHESIA and surgical procedures. Bioactivity details MOA
An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting. Bioactivity details MOA
A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae. Bioactivity details MOA
Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. Bioactivity details MOA